Tactile Medical (TCMD) Q1 2025: AfloVest Airway Revenue Jumps 22% as Lymphedema Rebuilds Sales Force
AfloVest, airway clearance device, delivered standout growth as Tactile Medical’s lymphedema business absorbed a planned sales force reset and technology rollout. Management’s playbook is now focused on rapid sales hiring, CRM productivity, and deeper channel penetration—setting up a pivotal back half for execution and leverage.
Summary
- Airway Business Outpaces Expectations: AfloVest’s DME partnerships and priority placements fuel robust growth.
- Lymphedema Sales Reset Underway: Sales force optimization and CRM rollout temporarily pressure productivity and revenue mix.
- Execution in Back Half Critical: Success hinges on rapid sales hiring, CRM adoption, and channel rebalancing to restore momentum.
Performance Analysis
Tactile Medical’s Q1 results reveal a business in the midst of a strategic reset. Revenue edged up slightly, but the composition was sharply divergent: lymphatic therapy device sales declined 3% YoY as the company intentionally reduced sales headcount to optimize roles and territories, while airway clearance revenue surged 22% YoY on the strength of AfloVest’s growing DME, or durable medical equipment, channel partnerships and preferred placements. Gross margin improved by 290 basis points, driven by lower manufacturing and warranty costs, but operating loss widened as planned investments in technology and sales infrastructure weighed on the bottom line.
Management’s decision to pause hiring during a territory optimization project led to a reduction in field reps from 280 to 264, directly impacting lymphedema revenue and channel mix. At the same time, the launch of a new Salesforce CRM, customer relationship management, system required significant rep training and adaptation, temporarily reducing productivity. Despite these headwinds, airway clearance results and early Nimble, next-generation basic pump, adoption signal market traction for newer offerings. The company exited Q1 with $83.6 million in cash, after deploying $10 million for share repurchases.
- Sales Force Realignment: Temporary reduction in reps and CRM learning curve drove lymphedema revenue shortfall, with productivity expected to recover as hiring accelerates.
- AfloVest Channel Penetration: Priority DME agreements and physician education delivered double-digit airway growth and reinforced Tactile’s #2 market position.
- Margin Expansion: Gross margin gains reflect improved product design and collections, offset by higher tech and sales investments.
Execution in Q2 and the second half will be defined by the pace of sales hiring, CRM adoption, and the ability to rebalance channel coverage, particularly in commercial and VA lymphedema segments.
Executive Commentary
"We are making high value investments and operational enhancements that will best position our business for mid and long-term success."
Sherry Dodd, Chief Executive Officer
"Our 2025 total revenue guidance range assumes that growth for our lymphedema product line will be 4% to 5%, and growth for our airway clearance product line will be 20% to 23%."
Elaine Berkemeyer, Chief Financial Officer
Strategic Positioning
1. Sales Force Optimization and Territory Realignment
Tactile Medical initiated a full sales force optimization—analyzing headcount, roles, and geographic coverage to align with growth targets. The pause in backfilling vacancies created a temporary drop in field resources, but management expects to exceed 285 reps by Q2 and over 300 by year-end, the highest in company history. This will enable deeper penetration across vascular, oncology, and VA channels and is a critical lever for restoring lymphedema growth.
2. Technology-Driven Productivity and Workflow Modernization
The mid-February Salesforce CRM launch is central to Tactile’s push for data-driven sales execution. While initial adoption created a short-term productivity drag, management believes the system’s analytics and workflow tools will boost efficiency and territory coverage as reps gain proficiency. The Parachute e-prescribing platform, now generating a quarter of Nimble orders, and an upcoming AI documentation pilot are designed to further streamline order management and accelerate revenue conversion.
3. Product and Channel Expansion
AfloVest’s airway clearance business is a bright spot, benefiting from prioritized DME partnerships and increased physician education. Nimble’s rapid adoption, especially in vascular and Medicare channels, demonstrates demand for lighter, more user-friendly basic pumps. However, lymphedema channel mix was negatively affected by sales force vacancies, limiting FlexiTouch performance in oncology and VA segments. Management expects channel balance to normalize as hiring and CRM adoption ramp in Q2 and beyond.
4. Enhancing Patient Engagement and Data Insights
The Kylie digital engagement tool, with nearly 50,000 patient profiles and 1 million check-ins, is becoming a differentiated asset for patient education, therapy tracking, and data-driven product innovation. Centralizing patient education and support teams under a new leader aims to improve the patient experience and drive higher therapy compliance, supporting long-term retention and value capture.
Key Considerations
This quarter marks a transition phase, with near-term disruption expected to yield mid-term operational leverage and channel expansion. Investors should weigh the following:
- Sales Hiring Velocity: Achieving over 300 field reps by year-end is pivotal for recapturing lymphedema growth and restoring coverage in key channels.
- CRM Productivity Ramp: The pace at which reps master the new Salesforce CRM will determine how quickly productivity rebounds and territory optimization pays off.
- Channel Mix Normalization: Restoring oncology and VA coverage is essential for FlexiTouch and commercial lymphedema growth, offsetting current Medicare-heavy mix.
- Airway Growth Sustainability: AfloVest’s DME momentum must be maintained through continued partner alignment and physician education to deliver on high growth guidance.
- Technology and AI Leverage: Ongoing investments in e-prescribing, workflow automation, and patient engagement tools are intended to drive scalable efficiency and data-driven insights.
Risks
Execution risk remains elevated as the company accelerates hiring and navigates a major CRM transition, with a six to nine month rep productivity ramp. Tariff exposure on cost of goods sold, though actively managed, could pressure margins if mitigation strategies fall short. Competitive dynamics in both the lymphedema and airway clearance markets require continued innovation and channel engagement to sustain share gains and pricing power.
Forward Outlook
For Q2, Tactile Medical guided to:
- Revenue of $73 to $76 million, reflecting continued lymphedema headwinds and strong airway clearance growth
For full-year 2025, management revised guidance to:
- Total revenue of $309 to $315 million, with lymphedema growth of 4% to 5% and airway clearance growth of 20% to 23%
- Gross margin of 74% and operating expense growth of 9% to 11%, reflecting ongoing investment in sales and technology
- Adjusted EBITDA of $32 to $34 million, with up to $5 million in potential tariff impact
Management emphasized that the speed of sales hiring and CRM proficiency are the primary variables shaping the high and low ends of guidance, with Q3 expected to show a sharper sequential ramp than in past years.
Takeaways
Tactile Medical’s Q1 results highlight a company in strategic transition, with near-term lymphedema disruption offset by airway clearance strength and a clear roadmap for operational leverage.
- Airway Momentum: AfloVest’s DME-driven growth validates the channel partnership strategy and provides a template for other product lines.
- Lymphedema Reset: Sales force optimization and CRM deployment are necessary but disruptive, with recovery hinging on rapid hiring and rep ramp-up.
- Back Half Inflection: Investors should focus on Q3-Q4 execution, CRM adoption, and the ability to restore channel balance and productivity.
Conclusion
Tactile Medical is navigating a self-imposed reset to lay the groundwork for scalable growth, with airway clearance outperformance offering near-term support. The next two quarters will be critical for proving that sales force and technology investments can reignite lymphedema growth and deliver operating leverage.
Industry Read-Through
Tactile’s experience underscores the operational risk and opportunity of sales force rebalancing and technology modernization in medical device markets. As reimbursement and workflow complexity rise, companies that invest in CRM, e-prescribing, and patient engagement tools are better positioned for scalable growth but must manage near-term disruption. The DME channel’s role in driving device adoption is increasing, with partner alignment and education serving as key growth levers. Competitors should note the importance of channel mix management and the challenge of balancing innovation, coverage, and operational efficiency in a shifting reimbursement landscape.